NEW YORK, June 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Agilent Technologies Inc. (NYSE: A), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), RadNet, Inc. (NASDAQ: RDNT), Foundation Medicine, Inc. (NASDAQ: FMI) and Fluidigm Corporation (NASDAQ: FLDM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3529-100free.
--
Agilent Technologies Inc. Analyst Notes
On June 4, 2014, Agilent Technologies, Inc. (Agilent) announced an adjustment to the Company's reported Q2 2014 GAAP net income which was reported on May 14, 2014. The Company stated that it changed its Q2 2014 GAAP net income to $139 million, or $0.41 per share compared to the previously announced $150 million, or $0.45 per share. Agilent informed that in accordance with the disclosure in the Company's quarterly report on Form 10-Q filed on June 4, 2014, this change was made as a result of an out-of-period adjustment for tax expense. The full analyst notes on Agilent are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/A/report.pdf
--
Bio-Reference Laboratories Inc. AnalystNotes
On June 5, 2014, Bio-Reference Laboratories Inc. (Bio-Reference) reported its Q2 FY 2014 financial results (period ended April 30, 2014). Revenues increased by 14.1% YoY to $201.4 million, which is the highest recorded revenues in a quarter in its history. Net income totaled $10.3 million, or $0.37 per diluted share compared to $11.3 million or $0.41 per diluted share in Q2 FY 2013. Marc D. Grodman, MD, CEO, said, "As we have previously stated, we believe that we will just about equal our performance for the third quarter of last year in the coming third quarter of this year. We also believe that the fourth quarter will show improvement over the fourth quarter of last year." The full analyst notes on Bio-Reference are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/BRLI/report.pdf
--
RadNet, Inc. Analyst Notes
On June 5, 2014, RadNet Inc.'s (RadNet) stock increased to end the day at $7.00 compared to the previous day's closing price of $6.34, which represents a 10.41% growth. The Company's stock grew 12.0% over the past three trading days compared to the Nasdaq Composite which rose 1.39% and to the Dow Jones Industrial Average which rose 0.55% over the same trading period. The full analyst notes on RadNet are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/RDNT/report.pdf
--
Foundation Medicine, Inc. Analyst Notes
On June 4, 2014, Foundation Medicine, Inc. (Foundation Medicine) announced that it will be presenting at the Goldman Sachs Global Healthcare Conference on June 11, 2014, Wednesday at 4:00 p.m. PT in Rancho Palos Verdes, California. The Company stated that its President and CEO, Michael J. Pellini, M.D., will lead the presentation. Foundation Medicine stated that it will also be presenting at the JMP Securities Healthcare Conference wherein its Chief Operating Officer Steven J. Kafka, Ph.D., will be presenting on June 24, 2014, Tuesday at 3:00 p.m. ET in New York. Foundation Medicine informed that a listen-only live webcasts of the presentations and archive of the same for two weeks may be accessed through the Company's website. The full analyst notes on Foundation Medicine are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/FMI/report.pdf
--
Fluidigm CorporationAnalyst Notes
On June 3, 2014, Fluidigm Corporation (Fluidigm) announced that it has started shipping production volumes of its FLEXsix' integrated fluidic circuits (IFCs) to genotyping and gene expression customers. According to the Company, these IFCs would enable customers to either run each partition independently as separate experiments at separate times, or run multiple partitions simultaneously thus giving them new levels of flexibility for their Fluidigm-based experiments. "The FLEXsix IFC provides the flexibility to run variable numbers of samples and assays while maintaining all the benefits of Fluidigm's microfluidic IFCs, including an integrated workflow, low sample and assay consumption, and ultra-low cost," said Nico Tuason, Senior Product Manager at Fluidigm. The full analyst notes on Fluidigm are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/FLDM/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com or consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
